title: Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?
authors.affiliation: U.S. Terapia Molecolare e Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
authors.forename: Maria Rosa
authors.initials: MR
authors.lastname: Cappelletti
authors.affiliation: Department of Onco-Haematological and Internal Medicine, Section of Pathology University of Parma, Parma, Italy.
authors.forename: Letizia
authors.initials: L
authors.lastname: Gnetti
authors.affiliation: University Campus Bio-Medico Roma, Oncologia Medica, Roma, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Santini
authors.affiliation: U.S. Terapia Molecolare e Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Spada
authors.affiliation: Department of Anatomical Pathology, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Fox
authors.affiliation: U.S. Terapia Molecolare e Farmacogenomica, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Generali
keywords: FGFR inhibitors; FGFR2; endometrial cancer; everolimus